Ovarian Cancer

Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.

Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.

Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.

Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.

Marcia Goglia was given a laxative in the ER for what turned out to be ovarian cancer.

Diagnostic laparoscopy can play a role in predicting surgery outcomes for patients with ovarian cancer.

The best chemotherapy strategy (IP versus IV) for patients with ovarian cancer is still being debated. Franco M. Muggia, M.D., weighs in.

The Georgia Ovarian Cancer Alliance compiled a book of stories from women who were touched by ovarian cancer.

An expanded access program (EAP) was just opened up for ceratain patients with ovarian cancer to receive niraparib.

A recent study examined the relationship between polycystic ovarian syndrome, long or irregular periods and ovarian cancer risk.

Finding new biomarkers should be the top priority in ovarian cancer research, Maurie Markman, M.D., says.

The FDA approved Rubraca for patients with advanced ovarian cancer who already had two or more lines of therapy.

Psilocybin, a component found in psychedelic mushrooms, reduced cancer-related anxiety and depression in a recent trial.

Faced with cancer, some launch nonprofit organizations designed to help fellow patients and their families. Here’s how they do it.

The FDA expanded Avastin's approval to include patients with platinum-sensitive ovarian cancer.

A rock band made up of gynecologic oncologists is connecting with patients and their fans through rock music.

A phase 2 study is examining Keytruda in combination with two other agents for treatment of ovarian cancer.

A recently launched clinical trial is exploring a new agent to treat patients with advanced, recurrent, platinum-resistant ovarian cancer.

With the addition of PARP inhibitors, as well as new agents on the horizon, the treatment landscape of gynecologic cancers is progressing.

There are many misconceptions about genetic testing in cancer, but the SGO crafted a new toolkit to help patients and providers navigate the field.

Stress and depression can alter ovarian cancer tumors, often leading to poorer outcomes.

Optimizing the use of neoadjuvant chemotherapy could improve outcomes for patients with ovarian cancer.

A woman won a lawsuit against Johnson & Johnson, claiming that its baby powder caused her ovarian cancer.

Many female survivors of cancer face sexual pain after treatment, and may not feel comfortable starting a conversation with their health care providers.

Lynparza imrpoved progresion-free survival (PFS) when compared to the placebo group in a phase 3 ovarian cancer trial.

CURE spoke with Scott Richard, M.D., about ovarian cancer recurrence and barriers women may face the second time around.

A new toolkit developed by the Society for Gynecologic Oncology is aimed at increasing awareness about genetic testing for gynecologic cancers.

Mache Seibel discusses the benefits of taking estrogen supplements for women who harbor the BRCA genetic mutation.

A trial testing Zytiga's effectiveness in ovarian cancer was recently halted.